Pila Pharma Feed

	Est. tid*
2027-02-25	08:30	Bokslutskommuniké 2026
2026-08-27	08:30	Kvartalsrapport 2026-Q2
2026-04-22	N/A	Årsstämma
2026-02-26	08:30	Bokslutskommuniké 2025
2025-08-27	-	Kvartalsrapport 2025-Q2
2025-04-30	-	X-dag ordinarie utdelning PILA 0.00 SEK
2025-04-29	-	Årsstämma
2025-02-27	-	Bokslutskommuniké 2024
2024-08-27	-	Kvartalsrapport 2024-Q2
2024-05-17	-	X-dag ordinarie utdelning PILA 0.00 SEK
2024-02-28	-	Bokslutskommuniké 2023
2023-10-25	-	15-10 2023-Q3
2023-08-23	-	Kvartalsrapport 2023-Q2
2023-05-31	-	X-dag ordinarie utdelning PILA 0.00 SEK
2023-05-30	-	Årsstämma
2023-02-28	-	Bokslutskommuniké 2022
2022-10-26	-	Kvartalsrapport 2022-Q3
2022-08-26	-	Kvartalsrapport 2022-Q2
2022-06-08	-	X-dag ordinarie utdelning PILA 0.00 SEK
2022-06-07	-	Årsstämma
2022-04-26	-	Kvartalsrapport 2022-Q1
2022-02-18	-	Bokslutskommuniké 2021

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Bioteknik

2026-02-17 16:00:00 PILA PHARMA: MANAGEMENT TEAM COMMENTS ON OUTCOME OF TO2 WARRANTS

2026-02-17 12:00:00 PILA PHARMA ANNOUNCES THE OUTCOME IN THE EXERCISE OF WARRANTS OF SERIES TO2

2026-02-12 12:00:00 PILA PHARMA: Upcoming last days for exercise with the warrants of series TO2 1,12 SEK | -6,50% | 0,32 MSEK

2026-02-11 16:30:00 PILA PHARMA: CEO REPORT INTERVIEW AND Q&A ON CLINICAL PLANS, TO2 WARRANTS AND MORE, AVAILABLE FOR REPLAY NOW 1,20 SEK | -9,64% | 0,29 MSEK

2026-02-10 11:00:00 PILA PHARMA: INVITATION TO LIVE H2 / YEAR-END REPORT INTERVIEW AND Q&A TODAY AT 14:00 CET 1,33 SEK | -0,60% | 0,05 MSEK

2026-02-10 08:30:00 PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January - December 2025. 1,33 SEK | -0,60% | 0,05 MSEK

2026-02-09 15:00:00 PILA PHARMA PREPARES CLINICAL TRIAL APPLICATION IN RARE DISEASE ERYTHROMELALGIA 1,34 SEK | +10,78% | 0,17 MSEK

2026-02-05 08:45:00 THE EXERCISE PRICE FOR THE WARRANTS OF SERIES TO2 IN PILA PHARMA HAS BEEN DETERMINED TO SEK 1.50 AND THE EXERCISE PERIOD COMMENCES TODAY 1,19 SEK | +4,59% | 0,29 MSEK

2026-02-05 08:40:00 PILA PHARMA ACCELERATES THE PUBLICATION OF THE INTERIM REPORT OF THE SECOND HALF OF 2025 1,19 SEK | +4,59% | 0,29 MSEK

2026-01-27 08:55:00 PILA PHARMA: INVITATION TO LIVE Q&A TODAY, JANUARY 27, REGARDING PRECLINICAL STUDIES AND UPCOMING CLINICAL STUDIES 1,32 SEK | -9,22% | 1,36 MSEK

2026-01-26 11:00:00 PILA PHARMA SIGNS WITH NEW CLINICAL CRO TO PREPARE FOR CLINICAL PHASE IN OBESITY AFTER PRECLINICAL OBESITY STUDIES 1,45 SEK | -36,23% | 5,42 MSEK

2026-01-16 09:30:00 PILA PHARMA: CEO PARTICIPATED IN SWEDISH INVESTMENT PODCAST MARKET MAKERS 2,17 SEK | +3,33% | 0,76 MSEK

2026-01-16 08:30:00 PILA PHARMA: ANALYST GROUP INITIATES NEW EQUITY RESEARCH COVERAGE - BASE CASE TARGET OF SEK 6.30 2,17 SEK | +3,33% | 0,76 MSEK

2026-01-05 09:05:00 PILA PHARMA: INVITED TO PRESENT AT BIOTECH SHOWCASE / J.P MORGAN HEALTHCARE WEEK IN SAN FRANCISCO, JANUARY 13, 2026 1,96 SEK | -3,45% | 0,32 MSEK

2026-01-02 11:09:43 PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES 2,03 SEK | -1,46% | 0,46 MSEK

2025-12-19 08:45:00 PILA PHARMA: PRECLINICAL STUDIES OF XEN-D0501 IN OBESITY INITIATED 2,25 SEK | -2,17% | 0,37 MSEK

2025-12-04 16:00:00 PILA PHARMA ANNOUNCES PRE-CLINICAL OBESITY AND AMYLIN SPECIALIST PROFESSOR THOMAS LUTZ TO JOIN AS SCIENTIFIC ADVISER 2,12 SEK | -2,52% | 0,48 MSEK

2025-10-27 16:00:00 PILA PHARMA: UPCOMING PARTICIPATION IN OBESITYWEEK AND AMERICAN HEART ASSOCIATION CONVENTION 2,25 SEK | +1,12% | 0,17 MSEK

2025-10-07 11:45:00 PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES 2,43 SEK | +3,85% | 0,91 MSEK

2025-09-30 17:15:00 PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO GUBRA ON PRECLINICAL TRIALS OF XEN-D0501 IN OBESITY 2,13 SEK | -0,93% | 0,49 MSEK

2025-09-08 11:55:52 PILA PHARMA TO PARTICIPATE AT THE 61ST EASD DIABETES & OBESITY SCIENTIFIC MEETING, NEXT WEEK 16-19 SEPTEMBER IN VIENNA 2,24 SEK | -5,49% | 1,01 MSEK

2025-09-08 11:25:22 PILA PHARMA: ALL H1 REPORT & INVESTOR INTERVIEWS NOW ONLINE 2,24 SEK | -5,49% | 1,01 MSEK

2025-08-29 14:00:00 PILA PHARMA: H1 REPORT INTERVIEW RECORDING WITH DIREKT STUDIOS - CEO COMMENTS ON HEAVILY OVERSUBSCRIBED RIGHTS ISSUE AND PLANS 2,03 SEK | +2,22% | 0,45 MSEK

2025-08-29 13:30:00 PILA PHARMA: CEO VISITS INVESTMENT PODCAST 10X TO COMMENT ON HEAVILY OVERSUBSCRIBED ISSUE (293,5%) AND OBESITY PLANS 2,03 SEK | +2,22% | 0,45 MSEK

2025-08-27 08:00:00 PILA PHARMA PUBLISHES INTERIM REPORT (1 JANUARY - 30 JUNE 2025) 2,00 SEK | -4,31% | 0,41 MSEK

2025-08-21 15:55:00 PILA PHARMA: INVITATION TO LIVE H1 REPORT INTERVIEW AND Q&A 2,24 SEK | -5,49% | 0,28 MSEK

2025-08-21 15:30:00 PILA PHARMA ANNOUNCES THE COMPLETION OF REGISTRATION OF SHARES IN THE RIGHTS ISSUE AND ITS ASSOCIATED DIRECTED ISSUES, MARKING THE END OF THE RIGHTS ISSUE PROCESS 2,24 SEK | -5,49% | 0,28 MSEK

2025-07-31 15:30:00 PILA PHARMA announces updated dates for last day of trading with paid subscribed units and first day of trading in new shares 3,05 SEK | -8,82% | 0,13 MSEK

2025-07-23 08:55:00 The board of directors of PILA PHARMA has resolved to carry out a directed issue of units to underwriters in the previously ended rights issue 3,48 SEK | -0,71% | 0,21 MSEK

2025-07-21 13:45:00 PILA PHARMA announces the outcome of its oversubscribed rights issue and resolves on a directed issue for over-allotment 3,44 SEK | +2,23% | 0,44 MSEK

2025-07-14 13:20:00 THE LAST DAY OF SUBSCRIPTION OF UNITS IN PILA PHARMA'S RIGHTS ISSUE OF UNITS 3,76 SEK | +13,08% | 0,63 MSEK

2025-07-10 10:20:00 THE LAST DAY OF TRADING IN UNIT RIGHTS IN PILA PHARMA'S RIGHTS ISSUE OF UNITS 3,20 SEK | -15,57% | 0,39 MSEK

2025-07-09 09:25:32 PILA PHARMA: INVESTMENT PODCAST GÖTT TJÖT OM AKTIER INTERVIEWS CEO ABOUT RIGHTS ISSUE AND OBESITY ASPIRATIONS 3,79 SEK | +1,34% | 0,82 MSEK

2025-07-08 09:16:32 PILA PHARMA: FINWIRE SIT-DOWN INTERVIEW TALKING FUNDRAISING AND BET ON OBESITY 3,74 SEK | +31,69% | 0,76 MSEK

2025-07-07 11:30:00 PILA PHARMA: NEW INTERVIEW ON RIGHTS ISSUE AND BET ON OBESITY WITH DIREKT STUDIOS 2,84 SEK | +3,84% | 0,29 MSEK

2025-07-04 14:00:00 CEO DISCUSSES ONGOING RIGHTS ISSUE AND BET ON OBESITY WITH INVESTMENT PODCAST 10X 2,73 SEK | +8,32% | 0,18 MSEK

2025-07-01 10:41:00 The subscription period in PILA PHARMA's rights issue of units begins today 2,65 SEK | +1,73% | 0,12 MSEK

2025-07-01 09:05:00 PILA PHARMA DISCUSSES ITS FINANCING ROUND WITH HELGE LARSEN & PROINVESTOR 2,65 SEK | +1,73% | 0,12 MSEK

2025-06-25 13:30:00 THE LAST DAY OF TRADING IN PILA PHARMA'S SHARES INCLUDING THE RIGHT TO RECEIVE UNIT RIGHTS 2,98 SEK | -5,38% | 0,10 MSEK

2025-06-25 13:00:00 PILA PHARMA PUBLISHES PROSPECTUS IN CONNECTION WITH THE ANNOUNCED RIGHTS ISSUE OF UNITS 2,98 SEK | -5,38% | 0,10 MSEK

2025-06-19 15:20:00 THE BOARD OF DIRECTORS OF PILA PHARMA HAS RESOLVED TO CARRY OUT A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 20 MILLION 3,07 SEK | +4,39% | 0,05 MSEK

2025-06-18 13:48:36 PILA PHARMA: ALL INVESTOR PRESENTATION RECORDINGS NOW ONLINE 2,94 SEK | -7,95% | 0,06 MSEK

2025-06-17 14:48:42 PILA PHARMA VISITED DIREKT STUDIOS' INVESTMENT CHANNEL 3,20 SEK | -2,98% | 0,13 MSEK

2025-06-16 15:53:18 PILA PHARMA PARTICIPATED IN INVESTMENT PODCAST 10X 3,30 SEK | +5,72% | 0,22 MSEK

2025-06-10 17:00:00 PILA PHARMA INVITES TO AFTER-WORK MINGLE IN STOCKHOLM 2,65 SEK | -0,83% | 0,32 MSEK

2025-06-10 16:30:23 PILA PHARMA UPCOMING INVESTOR PRESENTATIONS IN STOCKHOLM 2,65 SEK | -0,83% | 0,32 MSEK

2025-06-10 11:01:01 PILA PHARMA DISCUSSED ITS POTENTIAL ROLE IN OBESITY & DIABETES WITH HELGE LARSEN & PROINVESTOR 2,65 SEK | -0,83% | 0,32 MSEK

2025-06-04 16:15:35 PILA PHARMA TO RE-VISIT PROINVESTOR WITH HELGE LARSEN TO DISCUSS THE COMPANY'S AMBITIONS IN OBESITY & DIABETES 2,69 SEK | +2,38% | 0,16 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Pila Pharma

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

Pila Pharma

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden